EUCTR2021-000672-11-DK进行中（未招募）1 期
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures
- •2. Adult male and nonpregnant, nonlactating female participants, 18 to 65 years (19-65 years of age in Republic of Korea) of age inclusive based on the date of the screening visit
- •3. Documented evidence of chronic HBV infection (eg, HBsAg positive for more than 6 months) with detectable HBsAg levels (> 1.5 log10 IU/mL) at screening
- •4. Screening electrocardiogram (ECG) without clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia’s formula) = 450 msec for males and = 470 msec for females.
- •5. Females of childbearing potential (as defined in Appendix 4 of the protocol must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline prior to enrollment
- •6. Male and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix 4 of the protocol. Must be willing and able to comply with all study requirements.
- •Participants in Cohort 1 should meet the following additional criteria to be eligible to participate in this study:
- •7. Have been on a commercially available HBV NUC treatment(s) (ie, TAF, TDF, entecavir, adefovir, lamivudine, telbivudine, either as single agents or in combination) with no change in regimen for 3 months prior to screening and willing to initiate TAF 25 mg.
- •8. Have a historical HBV DNA < LLOQ, measured at least once at local laboratory, 6 or more months prior to screening.
- •9. HBV DNA < LLOQ by central laboratory at screening
- •Participants in Cohort 2 and 3 should meet the following additional criterion at screening to be eligible to participate in this study:
- •10. HBV DNA > 2000 IU/mL (HBeAg-negative) and HBV DNA > 20,000 IU/mL (HBeAgpositive)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 115
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Extensive bridging fibrosis or cirrhosis as defined clinically by any 1 of the following:
- •a) Metavir = 3 or Ishak fibrosis score = 4 by a liver biopsy within 1 year of screening, or, in the absence of an appropriate liver biopsy, either:
- •b) Screening FibroTest score of > 0.48 and AST to platelet ratio index (APRI) > 1 by central laboratory, or
- •c) Historical (within = 6 months of screening) or current FibroScan with a result > 9 kPa
- •If liver biopsy is available, the liver biopsy result supersedes (b) and/or (c, if available)
- •If an appropriate liver biopsy is not available, fibrosis will be evaluated by (b) and/or (c, if available). In the event of discordance between (b) and (c), the FibroScan results will take precedence.
- •2. Participants meeting any of the following laboratory parameters at screening:
- •a) Hemoglobin < 12 g/dL (for males) or < 11 g/dL (for females)
- •b) White blood cell (WBC) count < 2500 cells/mm3
- •c) Neutrophil count < 1500 cell/mm3 (or < 1000 cell/mm3 if considered a physiological variant in a participant of African descent)
- •d) ALT = 2 x ULN (Cohort 1 only), ALT > 5 x ULN (Cohorts 2 and 3)
- •e) International normalized ratio (INR) > ULN unless the participant is stable on an anticoagulant regimen affecting INR
- •f) Albumin < 3.5 g/dL
- •g) Direct bilirubin > 1.5 x ULN
- •h) Platelet Count < 100,000/µL
- •i) Positive autoantibodies, defined as any one or more of the following:
- •i. Antinuclear antibodies (ANA) > 1:80
- •ii. Smooth muscle antibodies (anti-SMA) > 1:80
- •iii. Antimitochondrial antibodies (AMA) > 1:40
- •iv. Anti-thyroid peroxidase (anti-TPO) > 35 IU/mL
- •j) Estimated creatinine clearance (CLcr) < 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the screening evaluation, ie,
- •Male: ((140 – Age [years]) x (Weight [kg])) / (72 x (Serum Creatinine [mg/dl])) = CLcr (mL/min)
- •Female: ((140 – Age [years]) x (Weight [kg])) x 0.85 / (72 x (Serum Creatinine [mg/dL])) = CLcr (mL/min)
- •3. Participants in Cohort 2 and 3: Received OAV treatment for HBV within 6 months of screening. Participants who meet criteria for initiation of NUC treatment as judged by the principal investigator (PI) during screening should be excluded from Cohorts 2 and 3.
- •4. Co-infection with HIV, HCV, or hepatitis D virus (HDV). Participants who are HCV Ab or HDV Ab positive, but have a documented negative HCV RNA or HDV RNA, respectively, are eligible.
- •5. Current or prior history of HCC (eg, as evidenced by prior imaging) or screening a-fetoprotein = 50 ng/mL without imaging to rule out HCC
- •6. Current or prior history of clinical hepatic decompensation (eg, ascites, encephalopathy, or variceal hemorrhage).
- •7. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (eg, basal cell skin cancer). Participants under evaluation for possible malignancy are not eligible
- •8. Significant cardiovascular, ophthalmological, pulmonary, or neurological disease in the opinion of the investigator
- •9. Diagnosis of any autoimmune disease (eg, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, pneumonitis, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis, autoimmune nephritis, thyroiditis), poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), hemoglobinopathy, retinal disease, or are immunosuppressed
研究者
相似试验
进行中（未招募）
1 期
Hepatitis C Study with GT 1 2 and 3.Chronic Hepatitis C infectionMedDRA version: 20.0 Level: LLT Classification code 10076789 Term: Chronic hepatitis C genotype 2 System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10076831 Term: Chronic hepatitis C genotype 3 System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10076786 Term: Chronic hepatitis C genotype 1 System Organ Class: 100000004862EUCTR2016-002845-46-GBAlios BioPharma, Inc.161
进行中（未招募）
1 期
A study to determine how safe the treatment is for subjects diagnosed with hepatitis B virus infections when combined with other treatments for hepatitis B. Subjects must have no evidence of liver damage.Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB)MedDRA version: 20.1Level: LLTClassification code 10054283Term: HBV DNA detectableSystem Organ Class: 100000004848EUCTR2017-001647-12-PLArbutus Biopharma Corporation20
未知
1 期
A Phase 1b, Open-Label Study to Evaluate the Safety of AMG 479 in Combination with Gemcitabine as First-line Therapy for Metastatic Pancreatic CancerAdvanced solid tumorJPRN-jRCT2080221160Takeda Pharmaceutical Company Limited6
进行中（未招募）
1 期
study to assess how safe and how effective is Loncastuximab Tesirine together with Ibrutinib in patients with Advanced Diffuse Large B Cell Lymphoma or Mantle Cell LymphomaDiffuse large B-Cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002625-38-ITADC THERAPEUTICS SA161
进行中（未招募）
1 期
A study of the safety, pharmacokinetics and effects of seviteronel in men with prostate cancer that does not respond to hormone treatmentCastration-resistant prostate cancer (CRPC)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004103-20-GBInnocrin Pharmaceuticals, Inc.135